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In the present issue of Osteoarthritis and Cartilage, Deshmukh and 20 
colleagues identified a novel inhibitor of the Wnt-beta-catenin signaling 21 
pathway, SM04690, and demonstrated that, in mice, a single intra-articular 22 
injection was sufficient to protect from cartilage breakdown in a severe model of 23 
instability-induced osteoarthritis 1.  24 
The pharmacological nature of the compound, its favorable 25 
pharmacokinetic properties and the high tolerability in mice and humans 1,2, at 26 
least short term, make this finding extremely exciting, suggesting that the first 27 
disease-modifying drug for osteoarthritis, the leading cause of disability 28 
worldwide, is not anymore a mirage. 29 
WNTs are secreted proteins that, by engaging with their receptors, can 30 
activate several intracellular signaling pathways and elicit diverse types of 31 
responses in different cells, including modulation of proliferation, differentiation 32 
and acquisition of positional information. One such signaling pathway, the so-33 
called canonical WNT pathway, is mediated by the accumulation of the 34 
intracellular messenger beta catenin and the consequent activation of a 35 
transcriptional program mediated by TCF/LEF transcription factors (Fig. 1). 36 
Activation of the canonical WNT pathway in chondrocytes activates several 37 
processes that contribute to osteoarthritis progression including proliferation, 38 
loss of differentiation and, in mature chondrocytes it mediates hypertrophic 39 
differentiation 3 (Fig. 1). 40 
Mechanical injury and inflammation are potent inducers of WNT 41 
activation in cartilage 4,5. Targeting canonical WNT signaling was justified by 42 
abundant previous literature 3,: for instance an allele of the WNT inhibitor Frzb 43 
with diminished WNT-inhibitory capacity was found to be associated with 44 
osteoarthritis in two different genetic association studies in humans 6. In mice, 45 
loss of several molecules that suppress excessive activation of canonical WNT 46 
signaling, including Frzb 7, Wnt16 8, and Dot1l 9 resulted in increased WNT 47 
activation and osteoarthritis. 48 
The authors selected SM04690 by screening a library of compounds for 49 
their capacity to suppress canonical WNT signaling in cell lines, and 50 
subsequently in primary chondrocytes. Non-canonical WNT pathways, which 51 
also affect cartilage biology 10 were likely unaffected, at least based on regulation 52 
of target genes.  53 
As expected of a WNT antagonist, SM04690 supported chondrogenic 54 
differentiation of mesenchymal stem cells in vitro with an EC50 at the low 55 
nanomolar range. Less predictably, they also showed that SM04690 has also 56 
anti-catabolic properties in that it inhibited cartilage extracellular matrix 57 
breakdown and suppressed the expression of catabolic metalloproteinases.  58 
In vivo, a single intraarticular injection of 0.3 micrograms of SM04690 one 59 
week following severe destabilization prevented, to a certain extent, cartilage 60 
breakdown in rats.  61 
How could a single injection of a small compound result in such a long- 62 
lasting effect in joints that are still destabilized? The authors suggest that 63 
SM04690 has a pro-regenerative effect, but this is suggested only by the in vitro 64 
data, whereas, in vivo, there is no direct evidence of regeneration (e.g. better 65 
OARSI score after treatment than before). A different explanation may reside in 66 
the remarkable pharmacokinetic properties of SM04690: one hundred eighty 67 
days after a single injection the compound could still be detected well above 68 
therapeutic levels in the cartilage, but at much lower level in bone, and was 69 
hardly detected at any time point in the blood. These pharmacokinetic properties 70 
are not typical for a small compound and suggest that SM04690 might 71 
specifically bind and be retained in the cartilage. Accumulation and retention in 72 
the cartilage not only explain the prolonged effect, but also the absence of 73 
systemic adverse effects, which is also remarkable since WNT signaling is of 74 
great importance in the homeostasis of most organs and systems.  75 
Whilst our improved understanding of osteoarthritis pathogenesis has led 76 
to the discovery of several therapeutic effective targets 11, it is the remarkable 77 
specific and durable accumulation in cartilage that bring this technology 78 
significantly closer to clinical translation by affording prolonged activity and low 79 
toxicity.  80 
The main limitation of this study is that we do not know the exact 81 
mechanism of action of SM04690. Although it certainly suppresses excessive 82 
activation of WNT signaling, how is this achieved? What molecule(s) does 83 
SM04690 bind to? In fact, it is not clear if SM04690 suppresses WNT signaling 84 
directly or, for instance, by affecting other pathways that in turn suppress WNT 85 
signaling. The mechanism of action is of primary importance because several 86 
attempts to inhibit WNT signaling at genetic level have failed to treat 87 
osteoarthritis. For instance, Zhu et al. 12 inhibited canonical WNT signaling by 88 
overexpressing the WNT inhibitor ICAT in chondrocytes but this resulted in 89 
severe cartilage loss; Yasuhara et al. conditionally deleted beta catenin in 90 
cartilage postnatally, which resulted in loss of the cartilage progenitor cells 91 
expressing lubricin 13. On the other hand, for instance, DKK-1 overexpression in 92 
cartilage 14 or bone 15 improved the outcome of osteoarthritis in mice. 93 
One additional limitation is that SM04690 was administered one week 94 
after joint destabilization and therefore, although technically still in therapeutic 95 
regime, one week after severe joint destabilization is a very early time point, 96 
when osteoarthritis lesions are not fully established and the joint is in a state of 97 
acute inflammation which is uncharacteristic of established osteoarthritis. 98 
Therefore, this study does not closely represent what would be the typical 99 
scenario in osteoarthritis patients, but rather reproduces a situation similar to 100 
acute sports injuries, which ultimately predispose to osteoarthritis, or to very 101 
early osteoarthritis. The inflammation in the early post-traumatic phases is 102 
associated with activation of WNT signaling 4. It will be important to confirm 103 
whether SM04690 is effective also in advanced osteoarthritis, when there is 104 
established cartilage damage and marginal inflammation, or to be able to define 105 
patients with early osteoarthritis who are likely to progress and therefore to 106 
require treatment 16.  107 
The timing and duration of the intervention will also be important. While 108 
a prolonged and sustained activation of canonical WNT signaling is surely a 109 
pathogenic event, a brief burst of WNT activation drives tissue repair in many 110 
organs/systems including cartilage 3 (fig. 1) and it has been shown that a short-111 
controlled activation of this pathway also induces cartilage growth 3. This has 112 
implications for the delivery of the compound. One hundred eighty days is a long 113 
time for a mouse, but how does this translate to humans? What regime is right? 114 
Inevitably, the answers will come from the several clinical studies started by this 115 
group. 116 
All the authors but one are affiliated to the biotech company SAMUMED, 117 
who are pursuing clinical translation in humans. One completed phase I clinical 118 
trial demonstrated safety over 24 weeks in 61 patients 2 and, remarkably, also an 119 
improvement of the joint space width (JSW). Replication and longer time points 120 
will be needed in order to confirm the efficacy data for which this study is 121 
underpowered and not purposely designed. Additional two phase II and one 122 
phase III studies are ongoing. 123 
 124 
Figure legends  125 
 126 
Fig. 1. Inflammatory and mechanical stimuli activate canonical WNT signaling in 127 
cartilage. Controlled and transient activation ensures that homeostatic events 128 
take place and supports stem cell renewal. Excessive activation leads to 129 
osteoarthritis. 130 
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